| Document |
Document Title |
|
JP2008515848A |
The invention concerns a hydrophobic grafted collagen, a method for preparing same and use thereof, in particular in therapy. In the present invention, hydrophobic substances or molecules are grafted by covalent bonds on reactive amino a...
|
|
JP2008514655A |
Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 have the meaning indicated in Patent Claim ( 1 ), are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboemboli...
|
|
JP2008514703A |
Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.
|
|
JP2008514640A |
The present inventors have developed a novel composition and method for inhibiting inflammation and treating of symptoms of tissue ischemia, including that associated with peripheral and cardiac vascular disease by local administration o...
|
|
JP2008513436A |
The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydr
o-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such po...
|
|
JP2008513489A |
The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of admi...
|
|
JP2008513511A |
The invention relates to benzimidazole acetic acid compounds which function as antagonists of the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) receptor. The invention also relates to the use of ...
|
|
JP2008099565A |
To provide a sponge-like sheet for culturing cardiac muscles, making cardiac muscle-like tissues having a pulsating ability.This sponge-like sheet for culturing the cardiac muscles, comprising collagen and having many cylindrical spaces ...
|
|
JP2008513512A |
The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain...
|
|
JP2008512646A |
Methods are disclosed for the early non-invasive diagnosing of acute rejection (AR) in a transplanted subject, monitoring AR in a transplanted subject at risk of developing AR, preventing, inhibiting, reducing or treating AR in a transpl...
|
|
JP2008094855A |
To provide a vascular irrigation solution for suppressing pain, inflammation, spasm and restenosis.The vascular irrigation solution contains multiple agents selected from the group consisting of pain and inflammation suppressing agents, ...
|
|
JP2008512365A |
The invention relates to at least one chemical entity chosen from compounds of formula (I): and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I),...
|
|
JP2008094816A |
To provide an ultrasonic cancer therapy promoter which can remarkably improve a cancer therapy effect with ultrasonic waves, while ensuring high safety.This ultrasonic cancer therapy promoter contains metal semiconductor particles, and c...
|
|
JP2008512098A |
The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorde...
|
|
JP2008511652A |
The invention relates to methods for the promotion of wound healing. Specifically, methods for treating patients having wounds comprising administering the immunomodulator, Product R, are disclosed. Pharmaceutical compositions and kits c...
|
|
JP2008088186A |
To provide a method for isolating and using stem cell inhibiting factors for regulating the abnormal stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery, and further to provide a method for using the...
|
|
JP2008509935A |
Compositions and devices including hyaluronic acid and a compound that inhibits degradation of hyaluronic acid, and methods of making and using same.
|
|
JP4071105B2 |
The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an i...
|
|
JP2008063349A |
To provide a method for producing -(1,3)(1,6) glucan from gulcan-containing celluar source, treatment composition containing gulcan and the use/method of the treatment.This method comprises the following process: (a) the cells containing...
|
|
JP2008056565A |
To provide a medicine or a method which is effective for preventing or relieving delayed nerve cell death caused by ischemia or re-perfusion property of nerve cell.The medicine containing a Cl- channel blocker or a protein tyrosine kinas...
|
|
JP4060182B2 |
This invention provides a compound of the following formula: or salts thereof, and a compound of the following formula: or salts thereof, wherein Y 1 , Y 2 , Y 3 and Y 4 are independently selected from N, CH, etc.; R 1 is H, C 1-8 alkyl,...
|
|
JP2008050361A |
To provide pharmaceuticals in treating or preventing a disease or condition in which cannobinoid receptor activation plays a role.The present invention relates to naphthalene derivatives of formula (I), wherein X is S, S(O), S(O)2, S(O)2...
|
|
JP2008506768A |
The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB4 receptor antagonist. A method is provided for the use of such composition in the treatment, prevention, or i...
|
|
JP2008506754A |
The invention relates to the use of amphiregulin in the production of a medicament which can be used to treat acute hepatic injury and which is administered, for example, in order to: promote a primary endogenous protective reaction in t...
|
|
JP2008506718A |
The invention refers to pharmaceutical compositions based on oil extracted from the seeds of Carapa Guianensis Aublet and/or of chemical compounds isolated from this oil and responsible for its biological activity, the tetranortriterpeno...
|
|
JP2008044963A |
To provide a cryoprecipitatable blood plasma protein having been subjected to a virucidal heat treatment.The cryoprecipitatable blood plasma protein dried by freeze drying is prepared which is subjected to a severe terminal virucidal hea...
|
|
JP2008503584A |
The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical f...
|
|
JP2008503541A |
The present invention relates to human coagulation Factor VII polypeptides, as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions...
|
|
JP2008502672A |
There is provided a compound of formula (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inh...
|
|
JP2008502301A |
Sustained release formulations comprising molecules modified so as to have a reduced clearance is provided.
|
|
JP2008019273A |
To provide an AT1-receptor antagonist for preventing and treating postischemic renal failure and for protecting ischemic kidneys.The invention relates to the compound, (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(1H-tet
razol-5-...
|
|
JP2008502669A |
There is provided a compound of formula: (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which in...
|
|
JP2008501683A |
Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, a...
|
|
JP2008501622A |
The use of a compound of formula (I): in a method of manufacturing a medicament for the treatment or prophylaxis of a condition wherein inhibition of carboxypeptidase U is beneficial; specified compounds of formula (I) and compositions c...
|
|
JP2008501710A |
Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.
|
|
JP2008501032A |
The present invention provides a single high-purity liquid comprising a partially fluorinated ether liquid for use as a long-term tamponade agent. Compositions are directed to liquid tamponade agents consisting essentially of DFPE, or to...
|
|
JP2008501035A |
The present invention is directed to methods for ameliorating reproductive disorders. More specifically, the present invention describes methods and compositions for using IL-17 in the treatment of various infertility-related defects.
|
|
JP4033485B2 |
The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate and dextran sulphate for the manufacture of an agent capable of preventing or substantially reducing undesirable adhesion of damaged tis...
|
|
JPWO2005078072A1 |
To CD8 which has been activated and has caused damage to tissues and cells.+To provide regulatory T cells that suppress killer T cells. Activated CD8+CD8 as a regulatory T cell that suppresses the activity of killer T cells+CD122+Provide...
|
|
JP2007536898A |
The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at ...
|
|
JP2007536201A |
The present invention relates to compositions and methods useful in medical prophylaxis and treatment of a mammalian subject before and after exposure of the subject to potentially lethal pathogens and other insults. More specifically, t...
|
|
JP2007320971A |
To provide a new endothelin receptor antagonist. The pharmaceutical composition contains a compound of formula I or a pharmaceutically acceptable salt thereof. In the formula, R1is selected from a 1-6C alkyl, a 2-6C alkenyl, a 2-6C alkyn...
|
|
JP4021147B2 |
Methods for treating treating fibrosis in a mammal are described. An antifibrotic effective amount of a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr is administ...
|
|
JPWO2005084668A1 |
A drug for the prevention and / or treatment of ischemic cardiovascular disease, which is administered to a patient undergoing percutaneous coronary intervention, and is characterized by the following general formula (I). [Chemical 1]A d...
|
|
JP2007534361A |
The present invention discloses a device and a method for reducing the risk of hospital-acquired infections, nocosomial infections, originating from the insertion of the device and/or use of the device in the body of a human or animal. T...
|
|
JP2007297403A |
To provide a tissue adhesion-preventing agent after operation, containing an RGD-enriched gelatin. The tissue adhesion-preventing agent comprises an RGD-enriched gelatine wherein the proportion of RGD sequences related to the total numbe...
|
|
JP2007297402A |
To provide a polypeptide or peptide having improved, preferably high-degree cell-binding ability and selectivity, and to provide a cell-binding peptide or polypeptide providing no risk of infection by viruses and other pathogenic bacteri...
|
|
JP2007531737A |
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject...
|
|
JP2007530586A |
Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vag...
|
|
JP2007284410A |
To provide a medicament for promoting neurogenesis, effective for treatment of neurologic disease. The promoter of the neurogenesis contains (1) (i) an HGF protein or (ii) a peptide being a partial peptide of the HGF protein, and having ...
|
